International Flavors & Fragrances (IFF) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup is mixed-to-cautious — consensus has been revised down sharply in the final two weeks before the print, creating a potentially beatable bar, but the single biggest swing factor is whether the Middle East conflict headwind in Fine Fragrance is worse than the guided Q2 step-down and whether pricing surcharges are materializing fast enough to offset energy and logistics inflation.

Bar: Consensus for Q2 2026 revenue stands at ~$2.606B and Adjusted Operating EBITDA at ~$516M, both revised down meaningfully in the final two weeks of July (revenue cut ~$75M, EBITDA cut ~$12M from mid-July levels), suggesting the Street has already de-risked the quarter. Management explicitly guided for Q2 absolute EBITDA to be below Q1's $568M, driven by lower volume, unfavorable price-to-input costs, and Fine Fragrance mix weakness — the bar is now low enough that a modest beat is achievable if any of those three headwinds proves less severe than feared.

Guidance/Tone: Management's posture on the Q1 call (May 6) was cautiously confident — they reaffirmed full-year guidance of $10.5B–$10.8B revenue and $2.05B–$2.15B Adjusted EBITDA, but explicitly flagged a "different shape" to the year with a stronger Q1 and a more measured balance. Since then, the June 23 8-K disclosed a $1B term loan to refinance €800M of notes due September 2026, and separately confirmed the Food Ingredients sale process has advanced to second-round due diligence with a deal expected to generate ~$3.8B in net proceeds and close by end of Q2 2027 — both are balance-sheet positives that should not distract from the operating print.

Estimate Trajectory: Estimates were broadly stable from mid-May through mid-July, then dropped sharply in the week of July 24 — Q2 revenue fell from ~$2.681B to ~$2.609B (–2.7%) and Q2 EBITDA from ~$527M to ~$517M (–1.9%), likely driven by peer prints (Givaudan, DSM-Firmenich, Symrise all reported in late July) confirming Fine Fragrance softness and North America taste weakness. The gap between current consensus and the FY guidance midpoint ($10.625B) implies a meaningful H2 acceleration, which remains the key risk to the full-year story.

Stock Setup: IFF is up ~+14% over the past 3 and 6 months, driven almost entirely by multiple expansion (EV/EBITDA expanded ~+11% over 3 months) rather than estimate revisions, which have actually drifted lower. The stock trades at ~12.2x NTM EV/EBITDA — a discount to its historical range — suggesting the market has not fully priced in a successful turnaround. A clean Q2 print with reaffirmed full-year guidance could sustain the re-rating; a miss or guidance cut would likely reverse recent multiple expansion quickly.

Wildcard: The Food Ingredients sale process update is the single biggest potential catalyst. Management promised an update "by the Q2 earnings call" — if they announce a signed deal or a specific buyer at ~$3.8B in proceeds, the stock could react sharply positive regardless of the operating print, as it would crystallize the balance sheet transformation and accelerate the deleveraging/buyback story. Conversely, a delay or price reduction would be a significant negative surprise.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus has been cut sharply in the final two weeks of July, setting a low bar heading into the print. Adjusted Operating EBITDA is the bigger swing factor — the margin trajectory (guided step-down from Q1's 20.7%) is the metric most likely to drive the stock on results day, while revenue is a secondary read on volume recovery across segments.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data. Note: Q2 2026 consensus as of August 3, 2026. Q1 2026 Actual and Q2 2025 Actual are reported figures from Visible Alpha. YoY change compares Q2 2026 consensus to Q2 2025 actual. FY 2026 guidance from IFF Q1 2026 Earnings Call (May 6, 2026).

Table 2 — Beat/Miss History (Last 8 Quarters — Top 2 KPIs)

KPI 1: Total Revenue

KPI 2: Adjusted Operating EBITDA

Pattern: IFF has beaten revenue consensus in all 8 of the last 8 quarters, and beaten EBITDA consensus in 7 of the last 8 quarters (the lone miss was Q2 2025 at −0.2%), with an average EBITDA beat of ~+4.4% — a consistent track record of under-promising and over-delivering that supports the view that the current low bar is beatable. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year guidance has been reaffirmed unchanged since the Q1 print, but the shape of the year has shifted — a stronger Q1 front-loads the beat, while Q2 is explicitly guided lower, and H2 recovery remains the key execution risk. The only post-earnings corporate event was the June 23 term loan 8-K, which was a balance-sheet action, not an operational guidance update.

Source: IFF Q1 2026 Earnings Call Transcript (May 6, 2026); IFF Q1 2026 Earnings Release (May 5, 2026); IFF 8-K filed June 23, 2026; Visible Alpha Consensus Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates were broadly stable post-Q1 through mid-July, then dropped sharply in the final two weeks of July — Q2 revenue fell ~−2.7% and Q2 EBITDA fell ~−1.9% from mid-July levels, likely driven by peer prints confirming Fine Fragrance softness. Full-year estimates have also been cut, with FY consensus now sitting below the guidance midpoint, implying the Street is not fully crediting the H2 recovery story.

Source: Visible Alpha Consensus and Actuals Data. Baseline "~5 days post Q1" uses May 12, 2026 as-of date. Current consensus as of August 3, 2026. The sharp estimate cuts in the week of July 24 (visible in the weekly revision history) coincide with Givaudan (July 23), DSM-Firmenich (July 30), and Symrise (July 30) Q2 2026 earnings reports, which confirmed Fine Fragrance timing softness and North America taste weakness. Estimates are now tracking below the guidance midpoint on both revenue and EBITDA, implying the Street is not fully crediting the H2 recovery embedded in management's full-year guidance.

5. Stock Performance

Key Takeaway: The ~+14% rally over the past 3–6 months has been driven almost entirely by multiple expansion, not estimate revisions — EV/EBITDA expanded ~+11% over 3 months while estimates drifted lower, suggesting the re-rating reflects improving sentiment on the turnaround story (Food Ingredients sale, deleveraging, buyback authorization) rather than fundamental earnings momentum. The stock has given back ~−4% over the past month as peer prints confirmed Q2 headwinds, but the multiple remains below historical levels, leaving room for further re-rating if the turnaround executes.

Valuation Snapshot (as of August 3, 2026)

Source: Implied Platform — Stock Performance Decomposition (snapshot August 3, 2026). Primary valuation metric: EV/EBITDA (NTM), consistent with specialty chemicals sector convention. The 3M and 6M price gains are almost entirely explained by multiple expansion (+11% and +10% respectively), while 12M performance reflects a mix of multiple contraction (−4%) offset by estimate-driven gains. The 1M pullback (−4%) is consistent with the late-July estimate cuts driven by peer prints.

Key Events Since Last Earnings (May 6, 2026):

• May 6, 2026: Q1 2026 earnings beat — stock rallied sharply in after-hours; broad-based volume growth and highest EBITDA margin since Q2 2022.
• June 23, 2026: 8-K filed — $1B term loan secured to refinance €800M notes due September 2026; Food Ingredients sale agreement disclosed (~$3.8B net proceeds, close by Q2 2027).
• July 9, 2026: IFF announced Q2 2026 results release date of August 4, 2026.
• Late July 2026: Peer prints (Givaudan July 23, DSM-Firmenich July 30, Symrise July 30) confirmed Fine Fragrance timing softness and North America taste weakness — drove ~−2–3% estimate cuts for IFF Q2.

6. Material News & Developments (Since May 6, 2026)

Key Takeaway: The most important development since Q1 earnings is the formal announcement of the Food Ingredients sale at ~$3.8B in net proceeds — this crystallizes the balance sheet transformation and is the single biggest potential catalyst at the Q2 print if management provides a closing timeline update. The $1B term loan refinancing removes near-term debt maturity risk and is a secondary positive.

• June 23, 2026 — Food Ingredients Sale Agreement Announced (8-K): IFF disclosed it has entered into an agreement to sell its Food Ingredients business, expected to generate approximately $3.8 billion in net cash proceeds, with closing expected by end of Q2 2027. This is the most significant strategic milestone since the DuPont N&B merger integration began. The term loan credit agreement includes a mandatory prepayment clause requiring 100% of Food Ingredients sale proceeds to repay the new $1B facility. Implication: Crystallizes the portfolio simplification story; proceeds will accelerate deleveraging and fund the $500M buyback authorization.
• June 23, 2026 — $1 Billion Term Loan Secured (8-K): IFF entered into a $1B senior unsecured delayed draw term loan with Wells Fargo as administrative agent, available through September 25, 2026, maturing December 31, 2027. Proceeds will refinance €800M of 1.800% Senior Notes due September 25, 2026. Interest at Term SOFR + 0.875%–1.500% based on public debt ratings. Financial covenant: max net debt/EBITDA of 3.75x. Implication: Removes near-term refinancing risk; no commitment fee; terms consistent with existing $2B revolving credit facility.
• May 6, 2026 — Q1 2026 Earnings Beat (Earnings Call & Release): Revenue of $2.741B and Adj. EBITDA of $568M both beat consensus by ~+4% and ~+9% respectively. EBITDA margin of 20.7% was the highest since Q2 2022. Management reaffirmed full-year guidance but flagged Q2 step-down due to Middle East conflict (Fine Fragrance), energy/logistics inflation, and pricing surcharge timing. Implication: Strong Q1 "de-risks" the full year per management; sets a high sequential comparison for Q2.
• May 6, 2026 — Middle East Conflict Flagged as New Headwind: Management introduced the Middle East conflict as an unanticipated headwind not embedded in original February guidance, specifically impacting Fine Fragrance volumes in Q2 (slower market demand + customer supply chain disruptions such as packaging logistics into the region). Energy and logistics inflation running at double-digit increases. Implication: Key Q2 risk; management expects all three headwinds (volume, price-cost, mix) to improve in H2.
• May 6, 2026 — $500M Share Buyback Authorization: Following achievement of below 3x net leverage target (~2.5x at Q1), IFF authorized a $500M share repurchase program. Implication: Capital allocation inflection; first buyback authorization in years; signals management confidence in FCF trajectory.
• May 6, 2026 — Health & Biosciences Latin America Expansion: IFF announced startup of the Arroyito site in Argentina (first full fermentation-based enzyme production in Latin America) and opened a household care application laboratory at its Innovation Center in Brazil. Implication: Supports H&B growth in a high-growth region; consistent with mid-single-digit H&B growth trajectory.
• May 4, 2026 — Annual Meeting: IFF shareholders elected directors, ratified auditors, and approved executive compensation (8-K filed May 4, 2026). No material governance changes. Implication: Routine; no read-through for the print.
• Late July 2026 — Peer Earnings Read-Through (Analyst Implication): Givaudan (July 23), DSM-Firmenich (July 30), and Symrise (July 30) all reported Q2 2026 results confirming: (1) Fine Fragrance timing softness vs. high comparables; (2) Consumer Fragrance as a bright spot; (3) North America taste/flavors still soft; (4) Low single-digit input cost inflation in H2 with tariff refunds passed back to customers. These prints drove the ~−2–3% estimate cuts for IFF in the final two weeks of July. Implication: Bar has been appropriately reset; peer commentary broadly consistent with IFF's own Q2 guidance.

7. Insider Transaction Activity (Since May 6, 2026)

Key Takeaway: One notable open-market purchase by a director in early June — a discretionary buy of ~$1.1M at a time when the stock was trading in the low-$80s — is a modestly positive signal, though a single director transaction is not a strong conviction indicator. No insider sales were filed in the period.

Source: SEC Form 4 filing, Paul J. Fribourg (IFF), filed June 2, 2026. Only open-market buys and sells (Form 4 codes P/S) are included. No insider sales were filed in the May 6 – August 3, 2026 window. The absence of insider selling ahead of the Q2 print is a mild positive signal. The Fribourg purchase was discretionary (not under a 10b5-1 plan) and occurred approximately four weeks after the Q1 beat, suggesting conviction in the turnaround trajectory at then-current prices.

8. Peer Commentaries & Read-Through

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for IFF's H2 2026 recovery story — Consumer Fragrance is a clear bright spot, Fine Fragrance softness in Q2 is confirmed as timing-driven rather than structural, Health & Biosciences demand is robust, and input cost inflation in H2 is expected to be low single-digit with tariff refunds offsetting pricing. The key cautionary read-through is North America taste/flavors weakness persisting (Givaudan, DSM-Firmenich), which is the primary risk to IFF's H2 volume recovery assumption.

Methodology Note: Only commentary published in the last 60 days (June 3 – August 3, 2026) that discusses the peers' forward current reporting period (Q3 2026, H2 2026, or updated FY2026 outlook) is included below. Retrospective commentary about peers' own reported Q2 2026 results is excluded. All peer companies reported Q2 2026 results in late July 2026.

8.1 Givaudan (GIVN SW) — Most Direct Comp | H1 2026 Results Reported July 23, 2026

Relevance: Givaudan is the single most important read-through for IFF, with direct overlap across Fine Fragrance, Consumer Fragrance, Fragrance Ingredients, and Taste & Wellbeing. Givaudan's H1 2026 results and H2/FY2026 forward guidance are the most granular external data point available for IFF's Q2 setup.

Supportive Read-Throughs (H2 2026 / FY2026 Forward Outlook)

• Fine Fragrance — Timing, Not Structural: Givaudan's CEO stated that Fine Fragrance momentum is "strong across the world" and the pipeline "remains really good." The company expects "continued sequential improvement into H2, supported by healthy leading indicators and easing comparables." This directly supports IFF's guidance that Fine Fragrance will see "continued solid growth for the full year" despite Q2 softness.
• Consumer Fragrance — Bright Spot Confirmed: Givaudan expects "broad-based growth in consumer products" with "general growth momentum strong" and a pipeline that is "broad-based, going to continue." This is the most positive read-through for IFF's Consumer Fragrance business heading into H2.
• Input Cost Inflation — Low Single-Digit in H2, Manageable: Givaudan guided for "low single-digit inflation in the second half of the year" on input costs, with tariff refunds (following the Supreme Court decision) expected to be "passed back to customers, broadly offsetting the inflation-related pricing impact." CFO Stuart Harris confirmed: "on a net basis, we shouldn't expect to see any meaningful contribution of pricing in the second half." This is directly consistent with IFF's own guidance that pricing surcharges will build through Q2 and into H2.
• No Evidence of Customer Destocking: Givaudan's CFO stated: "We don't see anything other than strong recurring demand and no evidence of any stocking that we would expect to unwind in the second half." This removes a key bear case risk for IFF's H2 volume recovery.
• Working Capital Improvement in H2: Givaudan guided for "a meaningful improvement in working capital in the second half of the year" — a positive read-through for IFF's own FCF improvement priority.
• GLP-1 and Natural Colors as Structural Growth Drivers: Givaudan sees GLP-1 as a "significant opportunity" driving demand for sweet modulation, protein masking, and functional beverages. Natural colors pipeline is "very strong" with consumer demand to "move out of artificial color into natural colors." Both are relevant to IFF's Taste and Food Ingredients segments.

Cautionary Read-Throughs

• North America Taste & Wellbeing Remains Soft: Givaudan reported North America at −1.5% LFL in H1 2026, with consumers "remaining selective, particularly at lower income levels." The CEO acknowledged a "continued difficult market environment in North America" and noted a "bit of a time lag" for pipeline conversion into revenue. This is the primary cautionary read-through for IFF's Taste/Nourish segment in North America.
• Fragrance Ingredients Under Price Pressure: Givaudan's Fragrance Ingredients declined −4.1% LFL in H1 2026 due to price competition. This is a direct read-through for IFF's Fragrance Ingredients business, which management has already flagged as a de-emphasis area.
• Adjusted EBITDA Margin Guided at ~24% for FY2026: Givaudan's CFO guided for "plus/minus 24%" EBITDA margin for FY2026, noting "we don't expect the same level of H1-to-full-year contraction as we saw in 2025." While Givaudan operates at structurally higher margins than IFF, the directional stability is a positive read-through for IFF's own margin trajectory.

8.2 DSM-Firmenich (DSFIR NA) — Direct Comp Across All Segments | Q2 2026 Results Reported July 30, 2026

Relevance: DSM-Firmenich covers Fragrances, Flavors/Texture, and Health/Nutrition in one report — the most comprehensive single read-through for IFF's entire portfolio. Strong synergy execution commentary is also relevant to IFF's own integration story.

Supportive Read-Throughs (H2 2026 / FY2026 Forward Outlook)

• Fine Fragrance — "Continue Good Dynamics, Very Strong": DSM-Firmenich expects "continued good dynamics" in Fine Fragrance, "very strong," driven by wins and consumer demand, expected to "continue." While double-digit growth is preferred, management guided for moderation to "high single-digit" over time — consistent with IFF's own "solid growth, less than double-digit" guidance.
• Consumer Fragrance Normalizing but Still Healthy: DSM-Firmenich expects Consumer Fragrance to "normalize a bit going into the second half" from high single/double-digit rates. Fragrance Ingredients expected to be "a bit more stable throughout the year." Perfumery & Beauty (PAB) margin expected to return "back up to expected levels in Q3 and Q4" after one-off Q2 costs.
• Taste, Texture & Health (TTH) — ~4% Underlying Growth Continuing: DSM-Firmenich guided for TTH underlying growth of "around 4%" to continue into H2, with TTH margin expected to "improve further towards the 20% guided." Synergies are a key driver: "enzyme sales, probiotic sales, culture sales really taking off" as the company combines them with flavor and palatability. This is a strong positive read-through for IFF's Taste and Health & Biosciences segments.
• GLP-1 / Dairy Health Trend is Structural: DSM-Firmenich's dairy segment (~25% of TTH) is "benefiting from trends towards more healthy food, low sugar, low fat, low salt, but also benefiting from the GLP-1 trend where we look for more proteins, more fiber, more gut health." Management called this "structural" and expected to "continue to see." Direct read-through for IFF's Health & Biosciences and Taste segments.
• Health, Nutrition & Care (HNC) — ~4% Growth, Margin at 20%: DSM-Firmenich guided for HNC underlying growth of "around 4%" into H2, with HMO sales showing "very good traction" and eye health showing "first positive signals." HNC margin "nicely up to 20%." This is a positive read-through for IFF's Health & Biosciences segment.
• Good Start to Q3: DSM-Firmenich noted a "good start into Q3" with "a good month of July" — the most timely forward indicator available for IFF's Q3 setup.
• Tariff Impact Limited: DSM-Firmenich estimated tariff impact at "up to half a percent, maybe a little lower on a net net basis" for Q3/Q4, with net pricing (inflation net of tariffs) expected to be positive. "Not really material."

Cautionary Read-Throughs

• North America Consumer Behavior Remains Cautious: DSM-Firmenich does not expect "a change in business conditions" and assumes "the North American market remains a bit cautious in consumer behavior" for the remainder of the year, specifically impacting dietary supplements and eye health. This is a cautionary read-through for IFF's H&B North America recovery timeline.
• FX Headwind Persists into H2: DSM-Firmenich estimated a combined Q3/Q4 FX headwind of "around €25M," with impact of "a little over half a percent on margin." While fading, this is a reminder that FX remains a headwind for IFF as well, though IFF guided for ~+1% FX tailwind on sales.
• Cost Program One-Off Expense: DSM-Firmenich is implementing a restructuring targeting ~1,000 position reductions with a €100M one-off expense, with "a bit of impact in 2026 but the majority in 2027." Not directly applicable to IFF, but signals the industry is in a cost-reduction mode.

8.3 Symrise (SY1 GR) — Fragrance & Flavor Peer | Q2 2026 Results Reported July 30, 2026

Relevance: Symrise is a direct peer in Fragrances (Scent & Care, Aroma Molecules) and Flavors (Food & Beverage, Pet Nutrition). Its Q2 2026 results and H2/FY2026 guidance provide useful read-throughs on pricing dynamics and volume recovery.

Supportive Read-Throughs (H2 2026 / FY2026 Forward Outlook)

• Q3 Organic Growth Expected Similar to Q2 (~4.5%): Symrise guided that "current business momentum is expected to support Q3 organic sales growth similar to Q2" (Q2 was +4.5% organic). This is a positive read-through for IFF's H2 volume recovery.
• Fine Fragrance Decline in Q2 Was Timing, Not Structural: Symrise reported Fine Fragrance declined mid-single digit in Q2 against high prior-year comparables, but explicitly stated this "reflects timing rather than underlying customer engagement, which remained very strong." The company maintains a "very dynamic opportunity portfolio in fine fragrance." This directly validates IFF's own characterization of Q2 Fine Fragrance softness.
• Aroma Molecules Acceleration in H2: Symrise stated "acceleration will be visible in H2" for Aroma Molecules, with the company "doing a great job" in this area and focusing on replacing older molecules with "more modern and profitable" ones. Aroma molecules are a "value driver" and "strength" for Symrise due to backward integration.
• Pet Nutrition Recovery in H2: Symrise's CEO expressed "very confident" expectations for "much better performance than in Q1 and Q2" in Pet Nutrition in H2, with volumes returning as prices are "back to market reality." Price concessions are "very limited compared to last year" and prices "will not go lower." This is a positive read-through for IFF's animal nutrition exposure.
• North America Strong in Q2 (+9.6% Organic): Symrise reported North America organic sales growth of +9.6% in Q2, driven by "significant wins with key accounts." This is a more positive North America read-through than Givaudan's, suggesting company-specific execution matters.
• FY2026 Guidance Reaffirmed at 2–4% Organic Growth: Symrise reaffirmed FY2026 guidance of 2–4% organic growth, adjusted EBITDA margin of 21.5–22.5%, and free cash flow margin above 14%. Full-year confidence "supported by stronger commercial momentum, steady profitability and improved cash conversion."

Cautionary Read-Throughs

• Scent & Care Pricing Negative (−3.1% in Q2): Symrise reported negative pricing of −3.1% in Scent & Care in Q2, described as "tactical" to drive volume recovery. While the company expects to "offset this price decrease by better operational excellence" in H2, this is a cautionary read-through for IFF's Fragrance Ingredients pricing environment.
• Middle East Logistics Costs Impacted H1 Margins: Symrise flagged "higher logistics and certain raw material costs, particularly those related to the geopolitical situation in the Middle East" as a margin headwind in H1. The company is investing in logistics infrastructure to moderate these headwinds — consistent with IFF's own energy/logistics surcharge narrative.
• Terpene Divestiture Ongoing: Symrise is pursuing divestiture of its terpene ingredient business, with discussions "progressing constructively." Not directly applicable to IFF, but signals ongoing portfolio rationalization across the sector.

8.4 Sensient Technologies (SXT) — Natural Colors & Flavors | Q2 2026 Results Reported July 24, 2026

Relevance: Sensient is a read-through for IFF's natural colors and flavors businesses. Sensient's CEO also commented directly on IFF's divestiture of natural color assets to Nutra.

Supportive Read-Throughs (H2 2026 / FY2026 Forward Outlook)

• Natural Color Conversion Demand Accelerating: Sensient described the US conversion to natural colors as "the single largest opportunity in its history," with invoiced natural color conversion revenue of $25M in Q2 2026 (implying an annual run rate of "at least $100M, potentially $130M+"). Invoiced values expected to "rise in Q3 and rise again in Q4." Many customers targeting January 1, 2027 conversion deadline (Walmart, school lunch programs). This is a strong positive read-through for IFF's natural colors and food ingredients businesses.
• Flavors Group — Mid-Single-Digit Growth Expected for FY2026: Sensient's Flavors and Extracts Group is expected to deliver "local currency revenue growth of mid-single digits for the year" with EBITDA margins "in the high teens." The flavors group plays a critical role in natural color conversions through "taste masking platforms specific to disguising natural color off notes" — a growing demand driver.
• FY2026 Guidance Raised: Sensient raised FY2026 guidance to "high single to low double digit" local currency revenue growth and "mid to high teens" local currency EBITDA/EPS growth, up from prior "high single to double digit" guidance. This is a positive read-through for specialty ingredient demand broadly.
• Regulatory Tailwind — Red 3 Ban: The US ban on Red 3 (January 2027 for food/beverage/pet; January 2028 for pharmaceuticals) and Mexico's ban (mid-2028) are structural demand drivers for natural color solutions. Sensient's CEO noted "regulations tend to be really good for our business because it creates technical complexities and formulations for our customers."

Cautionary Read-Throughs

• IFF's Divested Natural Color Assets Were Not a Major Competitive Overlap: Sensient's CEO commented that IFF's divested natural color business (sold to Nutra) was "not a particularly large natural color business" and "fairly heavy in things like carmine and annatto, which tend to be on a different part of the market than we traditionally play in." This suggests IFF's remaining natural color exposure post-divestiture is limited, reducing the read-through relevance of Sensient's strong natural color growth for IFF going forward.
• No Further Tariff Refund Benefits in H2: Sensient received ~$5M of tariff refunds in Q2 (mostly in the color group) but stated "no additional refunds of any significance are expected in future periods." This is a minor cautionary note on the tariff refund tailwind that Givaudan also flagged as being passed back to customers.

8.5 Balchem Corporation (BCPC) — Human & Animal Nutrition | Q2 2026 Results Reported July 24, 2026

Relevance: Balchem is a read-through for IFF's Health & Biosciences segment, particularly animal nutrition and human nutrition/health ingredients. Balchem's commentary on demand trends, Middle East input cost impacts, and margin management is directly relevant.

Supportive Read-Throughs (H2 2026 / FY2026 Forward Outlook)

• Demand Trends Remain Healthy Across All Businesses: Balchem stated "demand trends across our businesses remain healthy" and expressed confidence in "continued growth and margin performance going forward" despite higher Middle East-related input costs, citing "mitigating actions and growth-driven operating leverage." This is a positive read-through for IFF's H&B segment.
• Human Nutrition & Health — Above-Market Growth Continuing: Balchem expects its "unique portfolio, strong market positions, and focus on innovation to continue driving above-market growth within human nutrition and health." Consumer demand for "healthier nutritional solutions" (high protein, high fiber, lower sugar) continues to support growth. CFO expressed excitement about the "growth outlook for human nutrition and health."
• Animal Nutrition — Ruminant Portfolio Growing ~20% in Q2: Balchem's ruminant portfolio (higher margin, technology-driven) grew approximately 20% in Q2, "almost all volume growth." European Monogastric business recovering following EU anti-dumping duties, with "price recovery improving every quarter." Management is "pretty excited about what's ahead." This is a positive read-through for IFF's Animal Nutrition business within H&B.
• GLP-1 Targeting as a Marketing Opportunity: Balchem is shifting influencer marketing to target GLP-1 users for "nutrient-rich snacks and meal replacements" — consistent with Givaudan and DSM-Firmenich's commentary on GLP-1 as a structural demand driver for specialty nutrition ingredients.
• Choline Cognition Study Results Imminent: A clinical study on choline's impact on dementia/Alzheimer's (MD Anderson, University of Texas, MITA) is expected to be published "in the next couple of months." If results are positive, this could reinforce demand for choline-based ingredients and drive a follow-up larger study. Relevant to IFF's H&B innovation pipeline.

Cautionary Read-Throughs

• Middle East Conflict Driving Higher Input Costs: Balchem explicitly cited "higher input costs related to the conflict in the Middle East" as a headwind in Q2, though it was managed through "mitigating actions and growth-driven operating leverage." This is consistent with IFF's own energy/logistics inflation narrative and confirms the headwind is real and sector-wide.

8.6 Consolidated Peer Read-Through Summary

Sources: Givaudan H1 2026 Earnings Call Transcript (July 23, 2026); DSM-Firmenich Q2 2026 Earnings Call Transcript (July 30, 2026); Symrise Q2 2026 Earnings Call Transcript (July 30, 2026); Sensient Technologies Q2 2026 Earnings Call Transcript (July 24, 2026); Balchem Corporation Q2 2026 Earnings Call Transcript (July 24, 2026). All commentary reflects forward-looking statements made by management regarding H2 2026, Q3 2026, or updated FY2026 outlook — not retrospective commentary about reported Q2 2026 results.

Disclosures & Data Sources

Preparation Date: August 3, 2026. This report was prepared the day before IFF's Q2 2026 earnings release (August 4, 2026) and two days before the earnings call (August 5, 2026, 9:00 AM ET).

Data Sources:

• Visible Alpha Consensus and Actuals Data — All consensus estimates, actuals, and revision history. Consensus as of August 3, 2026 unless otherwise noted. Baseline estimates use May 12, 2026 as-of date (approximately 5 trading days post Q1 2026 earnings). Source: https://insights.visiblealpha.com/mex/IFF_US/
• IFF SEC Filings — Q1 2026 Earnings Release (8-K/EX-99.1, May 5, 2026); Q1 2026 Earnings Call Transcript (May 6, 2026); Term Loan 8-K (June 23, 2026); Annual Meeting 8-K (May 4, 2026). Source: SEC EDGAR.
• Peer Earnings Transcripts & Releases — Givaudan H1 2026 Earnings Call (July 23, 2026); DSM-Firmenich Q2 2026 Earnings Call (July 30, 2026); Symrise Q2 2026 Earnings Call (July 30, 2026); Sensient Technologies Q2 2026 Earnings Call (July 24, 2026); Balchem Corporation Q2 2026 Earnings Call (July 24, 2026).
• Insider Transaction Data — SEC Form 4 filing, Paul J. Fribourg (IFF), filed June 2, 2026. Source: SEC EDGAR (https://www.sec.gov/Archives/edgar/data/51253/000122520826005748/xslF345X06/doc4.xml).
• Stock Performance & Valuation Decomposition — Implied Platform, Stock Performance Decomposition module, snapshot August 3, 2026.
• Company Knowledge Base — Implied Platform, IFF Summary Knowledge, Key KPIs, and Earnings Revision Momentum modules.

Important Disclaimers:

• This report is prepared for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security.
• All consensus estimates are sourced from Visible Alpha and reflect analyst expectations as of August 3, 2026. Actual results may differ materially.
• Peer commentary reflects forward-looking statements made by third-party company managements and is subject to the risks and uncertainties disclosed in those companies' respective filings.
• The Food Ingredients sale (~$3.8B net proceeds) is subject to customary closing conditions and regulatory approvals; there is no guarantee the transaction will close on the expected timeline or at the expected price.
• Past beat/miss history is not indicative of future results.